Trials
Search / Trial NCT05640037

Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis

Launched by ZHONGNAN HOSPITAL · Nov 25, 2022

Apply for Trial

Trial Information

Current as of January 14, 2025

Completed

Keywords

Sepsis Interleukin 37 Biomarker

ClinConnect Summary

Sepsis patients admitted in the Department of Critical Care Medicine, Zhongnan Hospital will be included.

There are three groups of patients in this study: control group, sepsis group and septic shock group.

The interleukin-37 (IL-37) concentration in urine was analyzed in the day 1, 2, 4, 6.

Additionally, IL-37 concentration between blood stream infection groups and non-infection groups were analyzed. IL-37 concentration between survivors and non-survivors were also compared. IL-37 concentration were followed from day 1, 2, 4, 6.The correlation between the concentration of IL-37, IL-1β,...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • 1. Age 18 years or older
  • • 2. Expected length of stay\>24 hours in intensive care unit (ICU)
  • • 3. Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection
  • Exclusion Criteria:
  • • 1. anuria
  • • 2. ICU readmission in 28 days

Trial Officials

Dawei Wang, MD

Study Chair

Wuhan University

About Zhongnan Hospital

Zhongnan Hospital, affiliated with Wuhan University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on multidisciplinary collaboration, the hospital employs state-of-the-art facilities and a team of highly skilled professionals to conduct rigorous clinical studies aimed at improving patient outcomes. Zhongnan Hospital prioritizes ethical standards and patient safety, ensuring adherence to regulatory requirements while fostering a culture of scientific excellence. As a prominent sponsor of clinical trials, the hospital plays a pivotal role in contributing to the global medical community and enhancing the understanding of various health conditions.

Locations

Wuhan, Hubei, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials